Veloxis Pharmaceuticals

Veloxis Pharmaceuticals

NC - Cary
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Immunosuppression Therapies

Veloxis Pharmaceuticals is a life sciences company focused on Immunosuppression Therapies.

Neurology
Employees
5000+
Open Jobs
0

Products & Portfolio (1)

ENVARSUS XR
tacrolimus
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (an ubiquitous mammalian intracellular enzyme) is then formed and the phosphatase activity of calcineurin inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, gamma interferon, tumor necrosis factor-alpha, and granulocyte macrophage colony stimulating factor. Tacrolimus also inhibits IL-2 receptor expression and nitric oxide release, induces apoptosis and production of transforming growth factor-beta that can lead to immunosuppressive activity. The net result is the inhibition of T-lymphocyte activation and proliferation as well as T-helper-cell-dependent B-cell response (i.e., immunosuppression).
organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations
2015
15

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT03263052Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL
N/A
Tacrolimus
Renal Failure
N/A
Clinical Trials (1)
NCT02411604Expanded Access Study for Renal Transplant Patients With Envarsus XR ™
N/A
Conversion to Envarsus-XR and use of smart phone app, TransMedAx
Medication Adherence
N/A
Clinical Trials (1)
NCT04711291Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes
N/A
N/A
Clinical Trials (1)
NCT03703154Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus
N/A
Tacrolimus, Extended Release,
Kidney Transplant; Complications
Phase 1
Clinical Trials (1)
NCT03410654Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.
Phase 1
Phase 1
Clinical Trials (1)
NCT05238493A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101
Phase 1
Tacrolimus Extended Release Oral Tablet [Envarsus]
Kidney Transplant Rejection
Phase 1
Clinical Trials (1)
NCT03380936Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients
Phase 1
Phase 1
Clinical Trials (1)
NCT05251727Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
Phase 1
Tacrolimus Extended Release Oral Tablet [Envarsus]
Lung Transplant; Complications
Phase 1
Clinical Trials (1)
NCT04469842Early Use of Long-acting Tacrolimus in Lung Transplant Recipients
Phase 1
LCP-Tacro tablets
Renal Failure
Phase 2
Clinical Trials (1)
NCT01666951Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
Phase 2
LCP Tacro
Liver Failure
Phase 2
Clinical Trials (1)
NCT00608244Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients
Phase 2
Tacrolimus
Kidney Failure
Phase 2
Clinical Trials (1)
NCT00765661Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
Phase 2
Phase 2
Clinical Trials (1)
NCT04492436A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
Phase 2
Phase 2
Clinical Trials (1)
NCT07290777VEL-101 to Prevent Rejection After Kidney Transplantation
Phase 2
LCP Tacro
Renal Failure
Phase 2
Clinical Trials (1)
NCT00496483Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients
Phase 2
Phase 2
Clinical Trials (1)
NCT00608894LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
Phase 2
LCP -Tacro
Liver Failure
Phase 2
Clinical Trials (1)
NCT00772148Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients
Phase 2
LCP-AtorFen
Dyslipidemia
Phase 2
Clinical Trials (1)
NCT00504829Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
Phase 2
LCP-AtorFen
Dyslipidemia
Phase 2/3
Clinical Trials (1)
NCT0066485912-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT03386305Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT03321656Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
Phase 2/3
Phase 2/3
Clinical Trials (1)
NCT03769298CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients
Phase 2/3
Phase 3
Clinical Trials (1)
NCT01438710Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
Phase 3
LCP-Tacro
Renal Failure
Phase 3
Clinical Trials (1)
NCT00817206Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily
Phase 3
LCP-Tacro
Renal Failure
Phase 3
Clinical Trials (1)
NCT01962922Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.
Phase 3
Phase 3
Clinical Trials (1)
NCT01187953Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
Phase 3
Prograf vs Envarsus XR vs Astagraf XL
Renal Failure
Phase 3
Clinical Trials (1)
NCT02339246Pharmacokinetic Comparison Of All FK-506 Formulations
Phase 3
Phase 4
Clinical Trials (1)
NCT03461445Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients
Phase 4
Phase 4
Clinical Trials (1)
NCT03864926Envarsus in Delayed Graft Function (E-DGF)
Phase 4
Phase 4
Clinical Trials (1)
NCT03266393Envarsus XR® in Adolescent Renal Transplant Recipients
Phase 4
Extended-release tacrolimus
Kidney Transplant Rejection
Phase 4
Clinical Trials (1)
NCT04225988Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients
Phase 4
Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
Kidney Transplant
Phase 4
Clinical Trials (1)
NCT03713645Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients
Phase 4
Phase 4
Clinical Trials (1)
NCT03979365Envarsus XR Compared to Immediate Release Tacrolimus
Phase 4
Conversion to extended-release tacrolimus
Kidney Transplant Recipients
Phase 4
Clinical Trials (1)
NCT06751992Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
Phase 4
Twice-daily Tacrolimus
Kidney Transplantation
Phase 4
Clinical Trials (1)
NCT04773392Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
Phase 4
Extended Release Tacrolimus Tablets
Kidney Transplant; Complications
Phase 4
Clinical Trials (1)
NCT03841097Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants
Phase 4
Once daily immunosuppression regimen
Kidney Transplant; Complications
Phase 4
Clinical Trials (1)
NCT03555448Once Daily Immunosuppression Regimen
Phase 4
Change from Prograf to Envarsus XR
Renal Transplant
Phase 4
Clinical Trials (1)
NCT04838288Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XR™
Phase 4
Tacrolimus Extended Release Oral Tablet [Envarsus]
Kidney Transplantation
Phase 4
Clinical Trials (1)
NCT03828682Veloxis de Novo Kidney Transplant ECSWD
Phase 4
Phase 4
Clinical Trials (1)
NCT03823768Envarsus Neurotoxicity Burden in Liver Transplant Patients
Phase 4
Phase 4
Clinical Trials (1)
NCT04665310Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
Phase 4
Tacrolimus Extended Release Oral Tablet
Renal Transplant Rejection
Phase 4
Clinical Trials (1)
NCT03511560Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
Phase 4
Conversion from IR Tacrolimus to XR Tacrolimus
Chronic Kidney Diseases
Phase 4
Clinical Trials (1)
NCT04917718Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus
Phase 4
Phase 4
Clinical Trials (1)
NCT03760263Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2024
Portfolio: 1 approved product, 44 clinical trials
Top TAs: Nephrology
Portfolio Health
LOE Approaching1 (100%)
1 total products
Therapeutic Area Focus
Nephrology
1 marketed
Marketed
Pipeline